Acquiring drug candidate orismilast from Leo Pharma in summer of last year in a deal valued up to DKK 1.2bn (USD 186.4m) has turned out to be a good decision for Union Therapeutics.
Last month, the company entered into a strategic collaboration and license agreement about orismilast with the Chinese company Innovent Biologics, which could end up paying Union Therapeutics up to USD 267m for the exclusive rights to the research, development and commercialization of the drug in China, Hong Kong, Macau and Taiwan. It was also recently revealed that the US Food and Drug Administration has fast-tracked the former Leo Pharma eczema candidate, which is an oral treatment for atopic dermatitis, commonly known as eczema.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Fruergaard leveraging experience from Danish partnerships in key roles in Brussels
Experiences from Danish climate partnerships are among the tools that can be leveraged when Novo Nordisk CEO Lars Fruergaard begins stepping up efforts in the life science sector’s central organs in Brussels. ”I’ve been fired up by the intimacy and shared vision we could see in Denmark,” he tells MedWatch.
Stallergenes slapped with injunction
There are still issues with Stallergenes Greer’s factory in Antony, the Agence Nationale de Sécurité du Médicament has concluded.
Overview: Pharma giants and Bavarian Nordic fight over billion-dollar vaccine market
There is currently no approved vaccine for RSV, which causes serious illness and can be deadly for newborns and the elderly. The race to come first to the vaccine market is heating up, while more companies are close to completing phase III studies. Get an overview of their progress here.
Eargo raises USD 100m from investment firm
US-based Eargo, which is run by a Dane, has entered an agreement with an investment firm which is injecting USD 100m into the company.
US authorities expand monkeypox vaccine plan
More Americans will be offered a monkeypox vaccine.
Post Market Surveillance Department Manager 
Clinical Project Leader/ Sr. Clinical Trial Manager – make a difference and join our mission to bring our IL-22 lead program to patients 
Regulatory Affairs Manager - Maternity Cover 
Global Product Manager - ENT 
Chair of the Board 
Senior Toxicologist 
Medical Advisor 
Senior Clinical Trial Disclosure Associate 
Project Mgr for Medical Device Development 
Specialist within Project Management and Launch, Regulatory Affairs Life Cycle Management 
Project Managers keep all of us healthy 
Director Regulatory Affairs 
Principal Scientist – Pharmacology 
KLIFO is looking for a Project Director for our office in Denmark or Germany or Sweden 
Senior Project Manager (GMP - Life Science)